Cancer Drug Technologies Born in the Lab,
Leading to Global Technology Export and KOSDAQ Listing

New drug technologies originating in the laboratory have led to mega-sized technology transfer deals with global pharmaceutical companies and a listing on the KOSDAQ market, turning the commercialization potential of public research achievements into reality.


The Ministry of Science and ICT announced on the 5th that AimedBio Co., Ltd., which has grown through government support for new drug development R&D and startup exploration, has successfully carried out a large-scale technology export and completed a KOSDAQ listing, thereby establishing itself as a leading example of the diffusion of public research成果 into the market.

AimedBio CI. Provided by AimedBio

AimedBio CI. Provided by AimedBio

View original image

AimedBio is a company developing next-generation targeted anticancer drugs using antibody-drug conjugate (ADC) technology. Whereas conventional chemotherapeutic agents or monoclonal antibody therapies have involved issues such as damage to normal cells, limitations in target selectivity, and insufficient duration of efficacy, ADCs are evaluated as a next-generation anticancer modality that can act selectively on cancer cells and thereby enhance both therapeutic efficacy and safety.


Recently, the company signed a technology transfer agreement worth approximately 1.4 trillion won with the German global pharmaceutical company Boehringer Ingelheim, led by its new drug candidate for solid tumors, "ODS025." Subsequently, it listed on the KOSDAQ market on the basis of "AMB302," a new drug candidate with a novel mechanism of action, and recorded a market capitalization of about 2.8 trillion won on the first day of listing, demonstrating the value of deep-tech lab-based startups.


AimedBio's growth is closely linked to the government's full-cycle support structure that connects lab-stage technologies to market performance. In 2017, as a preliminary startup team, the company took part in "TeX-Corps," a public-technology-based, market-linked startup exploration support program of the Ministry of Science and ICT, and verified the marketability of its laboratory technologies. From 2021 onward, through R&D support from the pan-ministerial Korea Drug Development Fund program, it has progressively advanced key development stages such as non-clinical studies, developing its research成果 into actual new drug pipelines.


In this process, AimedBio carried out a total of 19 government projects, including TeX-Corps and the national new drug development program. It is assessed that a strategy that took market and patient needs into account from the early stages of research, combined with the government's full-cycle support for new drug development, enabled the company to grow into a global deep-tech enterprise just seven years after its founding.


Min Byung-gwi, Head of Research Center at AimedBio, said, "Through the TeX-Corps program, we were able to step outside the laboratory perspective and think deeply about what the market and patients truly want," adding, "We will establish ourselves as a new standard for the commercialization of public research成果 and as a company representing K-bio."



Kim Sung-soo, policy chief for R&D policy at the Ministry of Science and ICT, said, "AimedBio is a model case in which public research成果 have expanded beyond the laboratory into the market and industry," and added, "We will continue to strengthen full-cycle support for new drug development and the linkage to technology commercialization."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing